Testing a switch to a different chemotherapy type after heart side effects
Treatments studied
Part of Cancer, Heart & circulation clinical trials.
This study looks at whether people with solid tumors who develop heart-related side effects during a fluoropyrimidine chemotherapy can safely switch to a different fluoropyrimidine. It aims to see if the new option is feasible to use again when the first one caused cardiotoxicity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor (not leukemia/lymphoma)
- You had heart side effects while taking a fluoropyrimidine-based chemotherapy
- Your heart side effects were mild to moderate (grade 1 to 4)
- Your care team plans to try a re-challenge using a different fluoropyrimidine-based treatment
- You are not currently enrolled in a separate trial using experimental drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called FG-B901, either alone or with chemotherapy, for people with advanced solid tumors that haven't responded to standard treatment. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called FTL001 for people with advanced solid tumors that have not improved with standard therapy. The goal is to see if it is safe and how well it works.
This early-phase study (Phase 1) tests Hemay181, a new cancer medicine, in people with advanced solid tumors that have not been controlled by standard treatment. The goal is to see how the medicine works in the body and whether it can shrink or control tumors safely.
This trial tests a new combination of two investigational drugs, 7MW3711 and JS207, for people with advanced solid tumors that no longer respond to standard treatments. It aims to see if this combination is safe and effective.
This study tests an experimental antidote to help people who have had severe side effects or an overdose from common chemotherapy drugs called fluoropyrimidines (like 5-FU or capecitabine). The goal is to find the best dose and see if it can reduce the severity of these side effects.
This trial tests an experimental drug called Hemay5087 for people with advanced solid tumors. It aims to find out if the drug is safe and how well it works, offering a possible option when standard treatments have failed.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.